0001209191-23-059988.txt : 20231229
0001209191-23-059988.hdr.sgml : 20231229
20231229161216
ACCESSION NUMBER: 0001209191-23-059988
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231227
FILED AS OF DATE: 20231229
DATE AS OF CHANGE: 20231229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yednock Ted
CENTRAL INDEX KEY: 0001818525
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 231527793
MAIL ADDRESS:
STREET 1: C/O ANNEXON, INC.
STREET 2: 180 KIMBALL WAY, SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-27
0
0001528115
Annexon, Inc.
ANNX
0001818525
Yednock Ted
C/O ANNEXON, INC.
1400 SIERRA POINT PKWY, BLDG C, STE 200
BRISBANE
CA
94005
0
1
0
0
EVP & Chief Innovation Officer
1
Common Stock
2023-12-27
4
M
0
10615
1.4096
A
10615
D
Common Stock
2023-12-27
4
M
0
10385
1.8501
A
21000
D
Common Stock
2023-12-27
4
S
0
21000
4.5222
D
0
D
Stock Option (Right to Buy)
1.4096
2023-12-27
4
M
0
10615
0.00
D
2025-01-22
Common Stock
10615
0
D
Stock Option (Right to Buy)
1.8501
2023-12-27
4
M
0
10385
0.00
D
2026-08-11
Common Stock
10385
36000
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 28, 2023.
This transaction was executed in multiple trades in prices ranging from $4.50 to $4.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares subject to the option vest are fully vested and exercisable.
/s/ Jennifer Lew, as Attorney-in-Fact
2023-12-29